NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.09. The specialty pharmaceutical company had revenue of $13.93 million for the quarter, compared to analysts' expectations of $14.36 million. Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%. View Adamas Pharmaceuticals' Earnings History.

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

Adamas Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

10 brokers have issued 12-month price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 166.4% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

Media headlines about ADMS stock have been trending extremely negative on Saturday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Adamas Pharmaceuticals.

Adamas Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 15th total of 1,850,000 shares. Based on an average daily trading volume, of 658,300 shares, the short-interest ratio is currently 3.6 days. Approximately 10.7% of the company's shares are short sold. View Adamas Pharmaceuticals' Current Options Chain.

Some companies that are related to Adamas Pharmaceuticals include Axovant Sciences (AXON), Vectura Group (VEGPF), TherapeuticsMD (TXMD), Morphic (MORF), Kadmon (KDMN), Kura Oncology (KURA), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Prothena (PRTA), MacroGenics (MGNX), Clovis Oncology (CLVS), Viking Therapeutics (VKTX), Magenta Therapeutics (MGTA), BioDelivery Sciences International (BDSI) and Neoleukin Therapeutics (NLTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sangamo Therapeutics (SGMO), Abeona Therapeutics (ABEO), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Ardelyx (ARDX), Cara Therapeutics (CARA), Century Aluminum (CENX), Omeros (OMER) and TG Therapeutics (TGTX).

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $5.88.

Adamas Pharmaceuticals has a market capitalization of $163.81 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]